Novartis won approval for its multiple sclerosis drug Mayzent, which will launch at a price of $88,000 annually, according to Reuters. 1. Mayzent, an oral drug, was approved for adults with relapsing ...
Barchart on MSN
Should You Buy Novartis Stock Before October 28?
Switzerland-based global healthcare company Novartis (NVS) is gaining momentum this year, thanks to solid pipeline execution, ...
A U.S. court of appeals has reportedly ruled that a whistleblower case against Novartis (NYSE:NVS) over alleged kickbacks involving its multiple sclerosis drug Gilenya can proceed. The case further ...
Once-yearly infusions of rituximab are as effective as twice-yearly dosing for sustained control of MS in a new phase 3 trial ...
The National Multiple Sclerosis Society (Society) announces Shaping Tomorrow Together, a groundbreaking effort to highlight ...
The FDA on Tuesday approved Novartis’ generic version of Teva Pharmaceutical’s best-selling multiple sclerosis drug, Copaxone, reports Reuters. Here are three things to know. 1. Glatopa, manufactured ...
ZURICH (Reuters) - Swiss drugmaker Novartis on Friday stepped up its challenge to Roche's multiple sclerosis franchise, highlighting study results for its MS hopeful ofatumumab that could compete with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback